Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study (Mol Cancer Ther. 2023 Oct 2;22(10):1191-1203.) By lsc-webmaster Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study (Mol Cancer Ther. 2023 Oct 2;22(10):1191-1203.) Read More »
Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade (Mol Cancer Ther. 2022 Sep 6;21(9):1462-1472.) By lsc-webmaster Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade (Mol Cancer Ther. 2022 Sep 6;21(9):1462-1472.) Read More »
PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers (Mol Cancer Ther. 2020 Oct;19(10):2068-2078.) By lsc-webmaster PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers (Mol Cancer Ther. 2020 Oct;19(10):2068-2078.) Read More »
Quantitation of total antibody (tAb) from antibody drug conjugate (ADC) PYX-201 in rat and monkey plasma using an enzyme-linked immunosorbent assay (ELISA) and its application in preclinical studies (J Pharm Biomed Anal 2023 Sep 5:233:115452.) By Jonathan Quantitation of total antibody (tAb) from antibody drug conjugate (ADC) PYX-201 in rat and monkey plasma using an enzyme-linked immunosorbent assay (ELISA) and its application in preclinical studies (J Pharm Biomed Anal 2023 Sep 5:233:115452.) Read More »
Development and validation of a hybrid immunoaffinity LC–MS/MS assay for quantitation of total antibody (TAb) from an antibody drug conjugate (ADC) PYX-201 in human plasma (J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Aug 1:1228:123844.) By Jonathan Development and validation of a hybrid immunoaffinity LC–MS/MS assay for quantitation of total antibody (TAb) from an antibody drug conjugate (ADC) PYX-201 in human plasma (J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Aug 1:1228:123844.) Read More »
A sensitive and rapid LC-MS/MS assay for quantitation of free payload Aur0101 from antibody drug conjugate (ADC) PYX-201 in human plasma (J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Jul 15:1226:123786.) By Jonathan A sensitive and rapid LC-MS/MS assay for quantitation of free payload Aur0101 from antibody drug conjugate (ADC) PYX-201 in human plasma (J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Jul 15:1226:123786.) Read More »
A sensitive LC–MS/MS assay to quantitate free payload Aur0101 from ADC PYX-201 in rat and monkey plasma (Bioanalysis. 2023 Jul;15(14):833-843.) By Jonathan A sensitive LC–MS/MS assay to quantitate free payload Aur0101 from ADC PYX-201 in rat and monkey plasma (Bioanalysis. 2023 Jul;15(14):833-843.) Read More »
Bioanalysis of an antibody drug conjugate (ADC) PYX-201 in human plasma using a hybrid immunoaffinity LC–MS/MS approach (J Chromatogr B Analyt Technol Biomed Life Sci. 2023 May 15:1223:123715.) By Jonathan Bioanalysis of an antibody drug conjugate (ADC) PYX-201 in human plasma using a hybrid immunoaffinity LC–MS/MS approach (J Chromatogr B Analyt Technol Biomed Life Sci. 2023 May 15:1223:123715.) Read More »
Quantification of antibody–drug conjugate PYX-201 in rat and monkey plasma via ELISA and its application in preclinical studies (Bioanalysis. 2023 Jan;15(1):43-52.) By Jonathan Quantification of antibody–drug conjugate PYX-201 in rat and monkey plasma via ELISA and its application in preclinical studies (Bioanalysis. 2023 Jan;15(1):43-52.) Read More »
